Fang Ni - 21 Dec 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Chief Business Officer and interim Chief Financial Officer
Signature
Brent Hatzis-Schoch, as Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
21 Dec 2022
Net transactions value
+$72,366
Form type
4
Filing time
23 Dec 2022, 15:23:37 UTC
Previous filing
30 Jun 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Purchase $25,770 +20,000 +29% $1.29 89,026 21 Dec 2022 Direct F1
transaction BDTX Common Stock Purchase $46,596 +36,363 +41% $1.28 125,389 22 Dec 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.3099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

Officer Title: Chief Business Officer and interim Chief Financial Officer